However, this finding has scientific rationale and CDKN2A alterations have been associated with shorter PFS with other targeted therapies such as FGFR inhibitor futibatinib.42 Furthermore, we had already shown in tumor co-alteration studies that KRAS mutations were significantly associated with decreased ORR and decreased PFS, while PIK3CA demonstrated a trend toward a decrease in PFS.31 All of these findings may have therapeutic implications for combination therapy as well. The gene discussed is KRAS; the disease is neoplasm.